Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3566-3571

  Howell, Gina M ^a   Carty, Sally E ^a   Armstrong, Michaele J ^a   Lebeau, Shane O ^b   Hodak, Steven P ^b   Coyne, Christopher ^b   Stang, Michael T ^a   McCoy, Kelly L ^a   Nikiforova, Marina N ^b   Nikiforov, Yuri E ^b   Yip, Linwah ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AGED; AGING; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; RECURRENT CANCER; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 82955233568     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1781-5     Document Type: Article

References (22)

1. L Davies HG Welch 2006 Increasing incidence of thyroid cancer in the United States 1973-2002 JAMA 295 2164 2167 16684987 10.1001/jama.295.18.2164 1:CAS:528:DC%2BD28XksV2gtLg%3D
2. ID Hay GB Thompson CS Grant, et al. 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-99): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients World J Surg. 26 879 885 12016468 10.1007/s00268-002-6612-1 (Pubitemid 36920280)
3. EL Mazzaferri SM Jhiang 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer Am J Med. 97 418 428 7977430 10.1016/0002-9343(94)90321-2 1:STN:280:DyaK2M%2FmvVSgtA%3D%3D (Pubitemid 24345593)
4. L Vini SL Hyer J Marshall, et al. 2003 Long-term results in elderly patients with differentiated thyroid carcinoma Cancer. 97 2736 2742 12767085 10.1002/cncr.11410 (Pubitemid 36605140)
5. EL Mazzaferri RL Young JE Oertel 1977 Papillary thyroid carcinoma: the impact of therapy in 576 patients Medicine. 56 171 196 859443 10.1097/00005792-197705000-00001 1:STN:280:DyaE2s7ntVCmuw%3D%3D (Pubitemid 8111452)
6. MC Coburn HJ Wanebo 1995 Age correlates with increased frequency of high risk factors in elderly patients with thyroid cancer Am J Surg. 170 471 475 7485735 10.1016/S0002-9610(99)80332-8 1:STN:280:DyaK28%2Fms12ntw%3D%3D
7. ME Girelli D Casara R Rubello, et al. 1999 Differentiated thyroid carcinoma in the elderly: disease outcome, therapeutic approach, and long-term results in a group of 314 patients J Endocrinol Invest 22 Suppl 45 46 10727040 1:STN:280:DC%2BD3c7ovFGktg%3D%3D
8. GC Biliotti F Martini V Vezzosi, et al. 2006 Specific features of differentiated thyroid carcinoma in patients over 70 years of age J Surg Oncol. 93 194 198 16482598 10.1002/jso.20512 1:STN:280:DC%2BD287gs1GltA%3D%3D (Pubitemid 43381991)
9. ID Hay EJ Bergstralh JR Goellner, et al. 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 Surgery 114 6 1050 1057 8256208 1:STN:280:DyaK2c%2FnvVantA%3D%3D
10. M Xing 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev. 28 742 762 17940185 10.1210/er.2007-0007 1:CAS:528:DC%2BD1cXhtVKlsr8%3D (Pubitemid 350294294)
11. J-H Lee E-S Lee Y-S Kim 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid Cancer. 110 38 46 17520704 10.1002/cncr.22754 (Pubitemid 46986416)
12. M Xing WH Westra RP Tufano, et al. 2005 BRAF mutation predicts poorer clinical prognosis for papillary thyroid cancer J Clin Endocrinol Metab. 90 6373 6379 16174717 10.1210/jc.2005-0987 1:CAS:528:DC%2BD2MXhtlaltL7I (Pubitemid 41759286)
13. MN Nikiforova ET Kimura M Gandhi, et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab. 88 5399 5404 14602780 10.1210/jc.2003-030838 1:CAS:528: DC%2BD3sXptVyntrs%3D (Pubitemid 37452745)
14. E Kebebew J Weng J Bauer, et al. 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer Ann Surg. 246 466 471 17717450 10.1097/SLA.0b013e318148563d
15. C Lupi R Giannini C Ugolini, et al. 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma J Clin Endocrinol Metab. 92 4085 4090 17785355 10.1210/jc.2007-1179 1:CAS:528:DC%2BD2sXhtlartb7E (Pubitemid 350074715)
16. TY Kim WB Kim YS Rhee, et al. 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma Clin Endocrinol. 65 364 368 10.1111/j.1365-2265. 2006.02605.x 1:CAS:528:DC%2BD28XhtVOqtLjP
17. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
18. YE Nikiforov DL Steward TM Robinson-Smith, et al. 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules J Clin Endocrinol Metab. 94 2092 2098 19318445 10.1210/jc.2009-0247 1:CAS:528:DC%2BD1MXntFGmt7k%3D
19. Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute. J Natl Cancer Inst. 1997;89:1753.
20. Greene FL, Page DL, Fleming ID, et al., editors. Thyroid. In: American Joint Committee on Cancer: cancer staging manual, 6th edn. New York: Springer; 2002. p. 77-87.
21. G Riesco-Eizaguirre P Gutierrez-Martinez MA Garcia-Cabezas, et al. 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na +/I targeting to the membrane Endocr Relat Cancer. 13 257 269 16601293 10.1677/erc.1.01119 1:CAS:528:DC%2BD28XltlKrsr0%3D
22. M Schlumberger C Challeton F De Vathaire, et al. 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma J Nucl Med. 37 598 605 8691248 1:CAS:528:DyaK28XislKlurY%3D (Pubitemid 126618447)